UNSPSC 51282810: Metronidazole benzoate

This classification denotes a trichomonacide agent and protein synthesis inhibitor with the molecular formula C13H13N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A355C835XC, chemically known as 2-(2-methyl-5-nitroimidazol-1-yl)ethyl benzoate, but more generally known as metronidazole benzoate, which bears US NIH Compound Identifier 4173. European Medicines Agency schedules metronidazole benzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08922MIG.

Most nations, for tariff purposes, schedule metronidazole benzoate under HS 29332990. Metronidazole benzoate bears US NLM identifiers UMLS ID C0353490 and NCI Concept Code C87387. SMILES: CC1NCC(N1CCOC(=O)C2CCCCC2)[N+](=O)[O-].

UNSPSC 51282810 Metronidazole benzoate is a Commodity code that nominally covers a single antibiotic compound, but the recent state and local opportunities tagged under it show little alignment with the code's stated scope. The two most recent records involve pharmaceutical procurement by state health departments and county health agencies, but neither acquisition targets metronidazole benzoate specifically. Instead, the Illinois Department of Public Health's August 2026 piggyback contract through MMCAP Infuse awarded $2,999,999.11 to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets over a 12-month initial term with two renewal options, while Seminole County, Florida's June 2026 IFB solicited Naloxone and safe drug deactivation systems for quarterly delivery. The tagging suggests that state and local procurement systems may apply this code to broader pharmaceutical warehouse and emergency-response medicine acquisitions rather than to metronidazole benzoate as a discrete product line.

Activity under this code appears limited and geographically sparse. Illinois and Florida are the only states represented in the recent opportunity record, and both solicitations serve public health missions (pandemic preparedness and community overdose response) rather than a consistent commercial pharmaceutical category. The Illinois award was completed and closed, and the Florida opportunity carried a response deadline of July 26, 2023—now expired. Buyers interested in competing for pharmaceutical supplies under this code should note the mismatch between the code's nominal scope and actual procurement activity, and should verify code alignment with state and local procurement offices before pursuing opportunities, as the current tagging does not reliably signal metronidazole benzoate demand.